| P2093 | author name string | Apter A | |
| | Rubin K | |
| | Lukert B | |
| | Prestwood K | |
| | Frieri M | |
| | Brenner AM | |
| | Ledford D | |
| P2860 | cites work | Steroid-induced fractures and bone loss in patients with asthma | Q71773998 |
| | Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study | Q71802442 |
| | Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor | Q71934436 |
| | Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma | Q71960468 |
| | Effect of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: a longitudinal evaluation | Q71999009 |
| | Cyclical edidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis | Q72005655 |
| | Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin | Q72081327 |
| | Influences on skeletal mineralization in children and adolescents: evidence for varying effects of sexual maturation and physical activity | Q72082842 |
| | Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis | Q72113471 |
| | Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma | Q72123963 |
| | Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function | Q72133788 |
| | Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss | Q72359405 |
| | Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty | Q72577836 |
| | Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate | Q72584881 |
| | Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids | Q72767544 |
| | Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism | Q72811930 |
| | Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women | Q73911971 |
| | Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women | Q74424086 |
| | Epidemiology of osteoporosis | Q82943528 |
| | Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids | Q33557023 |
| | Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes | Q36986611 |
| | Clinical use of bone densitometry | Q37676918 |
| | Interaction of genetic and environmental influences on peak bone density | Q37845149 |
| | Epidemiology of osteoporosis and osteoporotic fractures | Q39832253 |
| | Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults | Q40526437 |
| | Hip fractures: a worldwide problem today and tomorrow | Q40716100 |
| | Bone Mineral Density in Adolescents | Q40983644 |
| | Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network | Q41005600 |
| | Hip fractures in the elderly: a world-wide projection | Q41104614 |
| | The osteoporosis revolution | Q41386704 |
| | A comparison of the efficacy and safety of inhaled corticosteroids in asthma | Q41559651 |
| | The crippling consequences of fractures and their impact on quality of life | Q41597014 |
| | Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate | Q42289291 |
| | A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group | Q42546292 |
| | Calcium supplementation and increases in bone mineral density in children | Q44376227 |
| | Thiazide diuretic agents and the incidence of hip fracture | Q45141401 |
| | Effects of heredity, age, weight, puberty, activity, and calcium intake on bone mineral density in children | Q46293672 |
| | Ethnic differences in hip fracture: a reduced incidence in Mexican Americans | Q46449726 |
| | Bone mineral density in normal and asthmatic children. | Q53787242 |
| | Bone density in adolescents. | Q53852247 |
| | Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. | Q54010104 |
| | Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis | Q57224532 |
| | Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management | Q60530953 |
| | Mineral balance and bone turnover in adolescents with anorexia nervosa | Q61479256 |
| | Growth of asthmatic children during treatment with alternate-day steroids | Q66919699 |
| | Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss | Q67505194 |
| | A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine | Q67967023 |
| | Effects of dose and dosing schedule of inhaled budesonide on bone turnover | Q68011572 |
| | Femoral neck and lumbar spine bone mineral densities in a normal population 3-20 years of age | Q68184091 |
| | Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study | Q68525402 |
| | Bone loss in response to long-term glucocorticoid therapy | Q68714839 |
| | Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids | Q68795603 |
| | Epidemiology of vertebral fractures in women | Q69737335 |
| | Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis. Four case reports and a critical commentary on the use of vitamin D in these disorders | Q69741069 |
| | Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases | Q69867009 |
| | Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) | Q69912312 |
| | Effect of calcium supplementation on bone loss in postmenopausal women | Q70532479 |
| | Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma | Q70838934 |
| | Testosterone therapy in glucocorticoid-treated men | Q71098016 |
| | Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography | Q71166814 |
| | Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids | Q71586494 |
| | Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines | Q71766973 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| | patient | Q181600 |
| | asthma | Q35869 |
| P304 | page(s) | 353-362 | |
| P577 | publication date | 1998-09-01 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Osteoporosis in the corticosteroid-treated patient with asthma. | |
| P478 | volume | 102 | |